Developed by Ascentage Pharma, lisaftoclax is a novel orally available Bcl-2 inhibitor with clinical benefits for an array of hematologic malignancies and solid tumors. At this year's ASH Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback